(Reported figures are for the full reporting period unless otherwise stated.
Figures for the comparable reporting period last year is stated in parenthesis
after realized figures.)

Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced results for the first
nine months of 2009. Exiqon expects full year revenue around DKK 130 million.
Net loss is expected around DKK 130 million.

• Revenue increased 3% to DKK 99.1 million (DKK 95.8 million). In the third
quarter of 2009, revenue decreased 21% to DKK 40.6 million (DKK 51.3 million)
due to one-time license revenue and associated reagent sales in the comparable
period of 2008.

• Operating expenses increased 16% to DKK 146.1 million (DKK 125.8 million). In
the third quarter of 2009, operating expenses increased 13% to DKK 48.8 million
(DKK 43.1 million) due to SG&A costs related to the diagnostics segment.

• Net loss was DKK 108.3 million (DKK 73.6 million). In the third quarter of
2009, net loss was DKK 27.2 million (DKK 10.1 million). EPS amounted to DKK
-3.58 (DKK -2.55) and DKK -0.90 (DKK -0.35) in the third quarter of 2009.

• On 2 July 2009, Exiqon Diagnostics announced two new marketing initiatives:
the launch of the ArQive™ Registry for clinical data collection, and the launch
of the new PortiQo™ Doctor Portal web based customer communication tool.

• In August, Exiqon Life Sciences was restructured and the cost base reduced by
approximately DDK 40 million on a full year basis to ensure a positive cash
flow from 2010.

• On 15 September 2009, Exiqon Life Sciences announced the successful
completion of several key milestones in a project for Tacere Therapeutics
designing custom-designed RNAi for Pfizer, Inc. for commercialization of a
potential single-administration treatment for Hepatitis C (HCV).

• After end period, on 15 October 2009, Exiqon Life Sciences launched its new
platform for quantitative real-time PCR analysis of microRNAs that combines all
the advantages of Exiqon's proprietary LNA™ detection technology with a
universal reverse transcription (RT) step, resulting in the most sensitive
microRNA expression profiling system available today.

• After end period, on 9 November 2009, Exiqon announced the appointment of
Mark Willig as Chief Commercial Officer who is joining Exiqon from a position
as Vice President of Global Sales for Thermo Fisher Scientific, Inc.

CEO Lars Kongsbak says: “We are very excited about the recent launch of
Exiqon's new platform for quantitative real-time PCR analysis of miRNAs and the
potential it holds for miRNA biomarker profiling in all sample formats not
least serum and FFPE samples. This important product launch follows a
successful reorganization of Exiqon Life Sciences. We are optimistic that this
product will allow Exiqon Life Sciences to cement its position as a leading
supplier of research products for miRNA profiling.”

See the full announcement at www.exiqon.com/investor/portal or in the attached
PDF.

announcement_20_q3_2009_final.pdf